This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Subscribe To Our Newsletter & Stay Updated
